美国2型糖尿病成人带状疱疹发病率与负担:一项回顾性数据库分析
该回顾性队列分析利用美国商业理赔数据(2012年1月1日至2018年7月31日),评估2型糖尿病(T2D)患者带状疱疹(HZ)发病率、医疗资源使用(HCRU)和费用。T2D患者HZ粗发病率为9.8/1000人年,无T2D者为2.6/1000人年,调整后发病率比(aIRR)为1.84(95%CI 1.82-1.85)。T2D合并HZ患者较单纯T2D患者12个月未调整增量全因医疗费用为5216美元。
要点
- T2D患者HZ粗发病率为9.8/1000人年,无T2D者为2.6/1000人年。
- T2D患者诊断为HZ的可能性几乎是无T2D者的两倍(aIRR 1.84;95%CI 1.82-1.85)。
- T2D合并HZ患者较单纯T2D患者12个月未调整增量全因医疗费用为5216美元。
核心结论
- 鉴于T2D患者HZ风险、HCRU和费用负担增加,对T2D患者进行HZ预防可能有益。
研究设计与样本
- 本回顾性队列分析使用美国商业理赔数据(涵盖2012年1月1日至2018年7月31日发生的理赔)。
主要发现
- T2D患者和无T2D患者的HZ粗发病率分别为9.8/1000人年和2.6/1000人年。
- T2D患者诊断为HZ的可能性几乎是无T2D者的两倍(aIRR 1.84;95%CI 1.82-1.85)。
- HZ与HCRU和医疗费用增加相关。
- 随访12个月时,T2D合并HZ患者较单纯T2D患者的未调整增量全因医疗费用为5216美元。
- T2D合并HZ患者较无T2D的HZ患者的未调整增量HZ相关医疗费用为2726美元。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Data on the real-world burden of herpes zoster (HZ) in adults with type 2 diabetes (T2D) in the U.S. are limited. We assessed HZ in patients with and without T2D and measured the impact of HZ on health care resource use (HCRU) and costs. RESEARCH DESIGN AND METHODS: This retrospective cohort analysis used U.S. commercial claims data (sourced from claims incurred between 1 January 2012 and 31 July 2018). HZ incidence rates/1,000 person-years (PYs) were calculated in patients with and without T2D. HZ risk was evaluated using Poisson regression to generate adjusted incidence rate ratios (aIRRs). Patients with T2D with HZ were propensity score matched to patients with T2D only and to patients with HZ without T2D. HCRU and costs were compared across cohorts during a 1-year follow-up period. Cox proportional hazards analyses evaluated factors associated with HZ-related complications. RESULTS: Crude HZ incidence rates in patients with and without T2D were 9.8/1,000 PY and 2.6/1,000 PY, respectively. T2D patients were almost twice as likely to be diagnosed with HZ (aIRR 1.84; 95% CI 1.82-1.85). HZ was associated with increased HCRU and health care costs. At 12 months, unadjusted incremental all-cause health care costs for patients with T2D with HZ versus patients with T2D without HZ were $5,216. The unadjusted incremental HZ-related health care costs for patients with T2D with HZ versus patients with HZ without T2D were $2,726. Age was the most important predictor for HZ-related complications. CONCLUSIONS: Given the increased risk of HZ and HCRU and cost burden in patients with T2D, HZ prevention in patients with T2D may be beneficial.
引用
- Poirrier JE, Meyers JL, Nagar SP, et al. Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Diabetes Care. 2022. PMID: 36149780. doi:10.2337/dc21-2053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。